|
Subjects
| |
27
|
28
|
|
Gender
|
Male
|
18
|
12
|
| |
Female
|
9
|
16
|
|
Mean Age at RT (range)
| |
52 ± 6 (25-82)
|
51 ± 5 (26-77)
|
|
Glioma Grade
|
Grade 3
|
8
|
9
|
| |
Grade 4
|
19
|
19
|
|
Racial-Ethnicity
|
Caucasian
|
25
|
26
|
| |
Asian
|
2
|
2
|
|
Surgical Co-Intervention
|
Biopsy-only
|
2
|
5
|
| |
Total Resection
|
16
|
6
|
| |
Subtotal Resection
|
9
|
17
|
|
Drug Co-intervention
|
Temodar
|
27
|
27
|
| |
Avastin
|
5
|
9
|
| |
Other
|
8
|
3
|
|
Median Karnofsky Perf. Scale (range)
| |
90% (70-100%)
|
90% (50-90%)
|
|
Mean RPA Classification
|
# of RPA Class III
|
8
|
8
|
| |
# of RPA Class IV
|
11
|
8
|
| |
# of RPA Class V
|
8
|
12
|
|
MGMT Status
|
Methylated
|
2
|
6
|
| |
Unmethylated
|
5
|
6
|
| |
Unknown
|
20
|
16
|
|
Tumor Localization
|
Frontal
|
6
|
11
|
| |
Temporal
|
12
|
10
|
| |
Parietal
|
4
|
3
|
| |
Occipital
|
2
|
1
|
| |
Other
|
3
|
3
|
|
Mean Bilateral PV Dose
| |
27 Gy ± 5
|
50 Gy ± 2
|
|
Median Ipsilateral PV Dose
| |
46 Gy ± 15.5
|
|
Median Contralateral PV Dose
| |
41 Gy ± 16.1
|
|
Median Ipsilateral HF Dose
| |
49.9 Gy ± 16.3
|
|
Mean Total Prescription Dose (range)
| |
52 Gy ± 4 (30-63)
|
57 Gy ± 2 (45-60)
|
